Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Securities (2022 - 2023)

Historic Securities for BioRestorative Therapies (BRTX) over the last 2 years, with Q4 2023 value amounting to $10.2 million.

  • BioRestorative Therapies' Securities fell 2189.4% to $10.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $10.2 million, marking a year-over-year decrease of 2189.4%. This contributed to the annual value of $10.2 million for FY2023, which is 2189.4% down from last year.
  • As of Q4 2023, BioRestorative Therapies' Securities stood at $10.2 million, which was down 2189.4% from $13.0 million recorded in Q4 2022.
  • Over the past 5 years, BioRestorative Therapies' Securities peaked at $13.0 million during Q4 2022, and registered a low of $10.2 million during Q4 2023.